Clinical utility of bone markers in the evaluation and follow-up of osteoporotic patients: why are the markers poorly accepted by clinicians?
Stepan
J J
JJ
3rd Department of Internal Medicine, Faculty of Medicine, Charles University, and Centre for Metabolic Bone Diseases of the University Hospital, Prague, Czech Republic. jstepan@mbox.vol.cz
D015415:Biomarkers / Q000032:analysis; D015519:Bone Density / Q000187:drug effects; D016723:Bone Remodeling / Q000187:drug effects; D001862:Bone Resorption / Q000517:prevention & control; D001842:Bone and Bones / Q000187:drug effects / Q000378:metabolism*; D050723:Fractures, Bone / Q000209:etiology / Q000517:prevention & control; D006801:Humans; D010024:Osteoporosis / Q000150:complications / Q000175:diagnosis* / Q000188:drug therapy / Q000378:metabolism*; D015663:Osteoporosis, Postmenopausal / Q000175:diagnosis / Q000378:metabolism; D011237:Predictive Value of Tests
D015415:Biomarkers